Adamis Pharmaceuticals Corporation (ADMP) News
Filter ADMP News Items
ADMP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADMP News Highlights
- ADMP's 30 day story count now stands at 2.
- Over the past 11 days, the trend for ADMP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ADMP News From Around the Web
Below are the latest news stories about Adamis Pharmaceuticals Corp that investors may wish to consider to help them evaluate ADMP as an investment opportunity.
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today announced that the compensation committee of the board of directors and the company’s independent directors approved the grant of stock options on February 15, 2022, to purchase an aggregate of 1 |
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now examine clinical and safety data from the first 50 subjects as part of the first interim analysis. COVID-19 is a complex disease that manifests in multiple phases including, among others, viral replication |
Adamis Pharma Updates 1 Key Risk Factor3 clinical trial in patients affected by COVID-19. Importantly, Tempol has demonstrated antiviral, anti-inflammatory, and antioxidant activity. While there have been recent approvals for oral antiviral drugs, Adamis noted Tempol’s unique mechanism of action and safety profile would offer an unmet medical requirement. With this development in mind, let us take a look at the changes in Adamis’ key risk factors that investors should know. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGrab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday! |
Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com |
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection. Tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. Although recent oral antiviral drugs ha |
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately. |
Adamis Pharmaceuticals (NASDAQ:ADMP) Stock Crosses Below 200 Day Moving Average of $1.00Adamis Pharmaceuticals Co. (NASDAQ:ADMP) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.00 and traded as low as $0.62. Adamis Pharmaceuticals shares last traded at $0.65, with a volume of 1,022,765 shares. A number of equities analysts have weighed in [] |
Adamis Pharmaceuticals (NASDAQ:ADMP) Raised to Hold at Zacks Investment ResearchZacks Investment Research upgraded shares of Adamis Pharmaceuticals (NASDAQ:ADMP) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the […] |
Adamis Pharmaceuticals (NASDAQ:ADMP) Shares Pass Below Two Hundred Day Moving Average of $1.00Shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.00 and traded as low as $0.66. Adamis Pharmaceuticals shares last traded at $0.68, with a volume of 2,135,672 shares trading hands. Separately, Zacks Investment Research downgraded shares of Adamis [] |